Y Intercept Hong Kong Ltd Sells 28,766 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Y Intercept Hong Kong Ltd decreased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 80.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,071 shares of the medical equipment provider's stock after selling 28,766 shares during the period. Y Intercept Hong Kong Ltd's holdings in Zimmer Biomet were worth $747,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. South Dakota Investment Council boosted its position in shares of Zimmer Biomet by 266.6% during the fourth quarter. South Dakota Investment Council now owns 80,886 shares of the medical equipment provider's stock worth $8,544,000 after buying an additional 58,820 shares during the period. World Equity Group Inc. acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $256,000. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in shares of Zimmer Biomet by 17.0% during the fourth quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 34,447 shares of the medical equipment provider's stock worth $3,639,000 after buying an additional 5,000 shares in the last quarter. Olympiad Research LP acquired a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $228,000. Finally, Callan Capital LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at $209,000. 88.89% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Barclays lowered their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a report on Monday, February 10th. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Stifel Nicolaus upped their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research note on Thursday, January 23rd. JMP Securities reiterated a "market outperform" rating and set a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. upgraded Zimmer Biomet from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $124.15.

Zimmer Biomet Stock Down 0.5 %

Shares of NYSE ZBH traded down $0.57 during trading on Tuesday, reaching $104.81. The company had a trading volume of 639,088 shares, compared to its average volume of 1,862,572. The business's 50-day moving average is $105.69 and its 200 day moving average is $107.32. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The stock has a market cap of $20.86 billion, a PE ratio of 23.55, a P/E/G ratio of 1.95 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the business earned $2.20 EPS. As a group, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. Zimmer Biomet's payout ratio is 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.